Fibraxis

Fibraxis is a female-founded UK biotech developing the world's first inhaled therapy to halt and reverse permanent airway damage in asthma. Our first-in-class small molecule targets the cellular mechanism driving irreversible airway remodelling, a pathway no approved drug currently addresses. Patent-protected, peer-reviewed, and delivered as a dry powder inhaler, it is designed as a preventative daily add-on for the 260 million asthma patients globally. Currently raising a GBP3M seed round ahead of MHRA Clinical Trial Authorisation.